Home › Companies › Trygg Pharma, Inc.

Trygg Pharma, Inc.

1 in Phase 3

Quick facts

Phase 3 pipeline

AKR-963 · Immunology
AKR-963 is a selective agonist of the adenosine A1 receptor that modulates immune and inflammatory responses.

Data from Drug Landscape. Machine-readable: markdown · JSON. Sources: SEC filings, FDA, ClinicalTrials.gov, press releases.